)
)
)
OS Therapies is a publicly traded (OSTX) clinical-stage biotech company focused on new therapeutics for osteosarcoma and other solid tumors. We have two platform technologies: 1) OST-HER2 is an off-the-shelf immunotherapy currently under regulatory review to be the first treatment ever in metastatic osteosarcoma, add first new therapy in osteosarcoma in over 40 years. Our other platform technology: 2) OST-tADC is a tunable ADC delivery system with ph-sensitive linkers and conditionally active, multiple payloads.
Year Founded
2018
Next catalyst (value inflection) update
FDA Approval - PRV
Expected time of next catalyst update
By September 2026
City
Grasonville
Country
United States
Company CEO or top company official
Paul Romness
Development Phase of Primary Product
NDA Preparation/In Review
Exchange
NYSE-A
Lead Product in Development
OST-HER2
Number of Unlicensed Products
2 Platform Technologies
Therapeutic Area
Oncology
Ticker
OSTX
Website
https://ostherapies.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
